Several pharma majors have started pondering in this space. This is evident from several recent developments, both in India, and also in other places of the world. One such articulation can be heard from the very top of the domestic … Continue reading
Tag Archives: Amgen
Making Drug Pricing Transparent May Work Better Than Price Control
“Now, one-fourth of the Indian pharma market to be under price control.” This possibility was reported by some national dailies, on July 03, 2018. The new methodology of drug price control could be anything – ranging from earlier ‘cost-based’ model to the … Continue reading
An Emerging Yo-Yo Syndrome With Biosimilar Drugs
Competition from Biosimilar drugs poses a threat of a combined revenue loss of estimated US$ 110 billion of those pharma players who are still enjoying market monopoly with patented biologic brands. This is expected to surely happen, in the long … Continue reading
Biosimilar Drugs: Why Prescriptions Aren’t Still Enough?
On September 3, 2015, in a Press Release, Novartis announced, “Zarxio(TM) (filgrastim-sndz) is now available in the United States. Zarxio is the first biosimilar approved by the US Food and Drug Administration (FDA) and the first to launch in the … Continue reading
A Great News! But…Would This ‘Golden Goose’ Lay Golden Eggs?
On December 9, 2014, international media flashed across the world a great news item from the Indian pharma industry: “The first biosimilar of the world’s top-selling medicine Humira (adalimumab) of AbbVie has been launched in India by Zydus Cadila.” This … Continue reading
More Glivec Like Deals in China and Mounting Global Challenges: Innovators poised Joining Biosimilar Bandwagon
Pressure from the emerging markets on pricing of patented products is mounting fast. This time the country involved is China. Recently, the Health Minister of China who stepped down last month after a seven-year stint in the top health job … Continue reading